Table 3.
% inhibition and seroconversion rate against SARS-CoV-2 variant of concerns.
| Time point | % Inhibition (median, IQR) | P-value | Seroconversion rate (n, %) | P-value | ||
|---|---|---|---|---|---|---|
| AZD1222 | BNT162b2 | AZD1222 | BNT162b2 | |||
| B.1.1.7 [Alpha] | ||||||
| 4-week after the 3rd dose | 97.0 (94.1, 98.1) | 96.4 (96.1, 96.7) | 0.015 | 90 (97.8) | 91 (98.9) | 1.000 |
| Before the 4th dose | 84.9 (65.7, 93.3) | 86.0 (70.9, 96.9) | 0.091 | 87 (94.6) | 89 (96.7) | 0.720 |
| 4-week after the 4th dose | 98.5 (98.2, 98.6) | 98.3 (98.1, 98.5) | 0.001 | 89 (98.9) | 91 (100.0) | 0.497 |
| B.1.351 [Beta] | ||||||
| 4-week after the 3rd dose | 91.8 (81.9, 95.8) | 93.8 (92.6, 94.5) | 0.184 | 88 (95.7) | 91 (98.9) | 0.368 |
| Before the 4th dose | 68.3 (41.6, 78.6) | 74.4 (55.7, 90.1) | 0.006 | 80 (87.0) | 89 (96.7) | 0.028 |
| 4-week after the 4th dose | 98.2 (97.7, 98.4) | 97.6 (96.8, 98.0) | < 0.001 | 86 (95.6) | 91 (100.0) | 0.059 |
| B.1.617.2 [Delta] | ||||||
| 4-week after the 3rd dose | 97.9 (96.8, 98.3) | 93.7 (92.8, 94.2) | < 0.001 | 90 (97.8) | 90 (97.8) | 1.000 |
| Before the 4th dose | 84.4 (61.8, 93.3) | 79.0 (62.0, 96.3) | 0.688 | 90 (97.8) | 89 (96.7) | 1.000 |
| 4-week after the 4th dose | 98.5 (98.2, 98.6) | 98.0 (97.7, 98.4) | < 0.001 | 86 (95.6) | 91 (100.0) | 0.059 |
| B.1.1.529 [Omicron] | ||||||
| 4-week after the 3rd dose | 62.9 (33.6, 79.6) | 81.7 (67.3, 91.1) | < 0.001 | 70 (76.1) | 83 (90.2) | 0.010 |
| Before the 4th dose | 12.7 (3.5, 28.8) | 16.1 (7.0, 36.8) | 0.123 | 20 (21.7) | 28 (30.4) | 0.179 |
| 4-week after the 4th dose | 92.9 (77.6, 96.3) | 83.0 (72.7, 92.0) | 0.001 | 84 (93.3) | 84 (92.3) | 0.789 |
The number of participants for AZD1222 was 92 after the third dose and before the fourth dose, and 90 after the fourth dose. The number of participants for BNT162b2 was 92 after the third dose and before the fourth dose, and 91 after the fourth dose.